Previous close | 16.64 |
Open | 17.24 |
Bid | 16.69 x 100 |
Ask | 16.77 x 100 |
Day's range | 16.68 - 17.52 |
52-week range | 11.83 - 28.80 |
Volume | |
Avg. volume | 730,359 |
Market cap | 821.465M |
Beta (5Y monthly) | 1.32 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Key Insights Significantly high institutional ownership implies REGENXBIO's stock price is sensitive to their trading...
Regenxbio Inc (NASDAQ:RGNX), a biotechnology company focused on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy, has reported an insider sale according to a recent SEC filing.
Regenxbio Inc (NASDAQ:RGNX), a biotechnology company focused on the development, commercialization, and licensing of recombinant viral vectors for use in gene therapy, has reported an insider sale according to a recent SEC filing.